Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
Date:5/9/2013

ss R&D associated with the license discussed below for Clonidine Topical Gel from Arcion Therapeutics (Arcion).

In addition to clinical development activities, BDSI also made an important stride forward in building its pipeline of products for the treatment of pain with the acquisition of patented Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN).  BDSI entered into a worldwide licensing agreement with privately held Arcion, where BDSI will develop and commercialize Clonidine Topical Gel. 

The effectiveness of Clonidine Topical Gel was previously assessed in reducing pain in PDN in a double-blind, placebo-controlled, Phase 2 study.  A significant treatment difference was seen in the pain intensity (p=0.01, n=63) in the planned subset analysis of diabetic patients who had documented evidence of functioning pain receptors in the skin of the lower leg.  At a minimum, this supports its effectiveness in diabetic patients with functioning pain receptors in the skin which accounts for approximately one-third to one-half of the nearly 26 million people that according to the American Diabetes Association are suffering from PDN.  BDSI plans to prepare for a confirmatory study in the latter part of 2013 which could lead to data availability by the end of 2014.  The PDN market is highly under-served by existing products, such as the oral medications Lyrica and Cymbalta.  BDSI estimates annual peak sales potential for the product in excess of $300 million in the U.S.

Under terms of the agreement, BDSI made an upfront payment of $2 million to Arcion in the form of unregistered shares of BDSI common stock.  No further milestone payments are due to Arcion until successful completion of the clinical development program and the filing of a New Drug Application (NDA). 

"BDSI continues to make remarkable progress in advancing its pipeline of BEMA products, BUNAVAIL and BEMA Bupren
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
2. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. R. Graham Cooks Wins Dreyfus Prize in the Chemical Sciences; Purdue Chemist Honored for Advances in Chemical Instrumentation
5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
6. Best Practices for Conducting Extractable and Leachable Studies, new life sciences webinar hosted by Xtalks
7. Tunnell Consulting Names John S. Ross as Principal, Life Sciences
8. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
9. Partnership between EBSCO Publishing and BioOne Online Journals Adds Scholarly Biological, Ecological and Environment Sciences Articles to EBSCO Discovery Service™
10. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
11. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... NC (PRWEB) March 05, 2015 ... that Pierre Noel, M.D., Professor of Medicine, Mayo ... the Company’s Board of Directors. , ... are extremely fortunate to have Dr. Noel, a ... leading healthcare organization, join Entegrion’s Board. His expertise ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... Thornton Cleveleys (UK) (PRWEB) March 05, 2015 ... Enhanced implantable polymer have received the CE mark (European) ... within the European Free Trade Association (EFTA) and the ... CE mark has now been granted to implants supplied ... degenerative disc spinal conditions. , Osimplant's Cervical Expandable ...
(Date:3/4/2015)... 2015 In an article published and posted ... Health Security review the clinical aspects of diseases caused ... bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," ... of the New England Journal of Medicine . ... , and Tom Inglesby—review the clinical management of conditions ...
Breaking Biology Technology:Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2
... ST. LOUIS, Oct. 25 Sigma-Aldrich(TM) (Nasdaq:,SIAL), a ... biotechnology products to the world,s researchers, and Oxford,BioMedica ... today that,they received a key order confirming the ... BioMedica and licensed exclusively in,the research field to ...
... Study Planned, WESTMINSTER, Colo., Oct. 25 ... company focused on,the development and commercialization of small ... that results from three PDX,studies were presented as ... 2007 in San Francisco, California. The posters,described the ...
... XTL Biopharmaceuticals,Ltd. (NASDAQ: XTLB )(LSE: XTL)(TASE: XTL) ... with institutional investors relating to,a private placement of ... of,ordinary shares, represented by American Depositary Receipts (ADRs). ... Sciences Fund, Quogue,Capital LLC, SCO Capital Partners and ...
Cached Biology Technology:Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 2Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 3Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 4XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 2XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 3
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... BEER-SHEVA, ISRAEL, May 3, 2010 Ben-Gurion University ... strain which produces large amounts of a polyunsaturated fatty ... blood cholesterol level, reducing the risk for heart attacks. ... Biotechnology Lab in the Jacob Blaustein Institutes for Desert ...
... keep the planet cool, but rising levels of carbon dioxide ... According to a new study by researchers at the Carnegie ... of the warming from increased carbon dioxide is due to ... to carbon dioxide,s better-known effect as a heat-trapping greenhouse gas. ...
... (May 3, 2010) Advances in energy conservation, better ... breakthroughs in understanding diseases: These are just a few ... be enabled by an upgrade to the Advanced Photon ... Argonne National Laboratory., DOE today announced formal approval for ...
Cached Biology News:Ben-Gurion U researchers isolate microalgal strain that could reduce cholesterol 2CO2 effects on plants increases global warming 2CO2 effects on plants increases global warming 3Upgrade to advanced photon source announced by DOE 2Upgrade to advanced photon source announced by DOE 3
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, 5 ... 0.3 ,Ferric ammonium citrate, 0.5 ,IPTG, ... water soluble, autoclavable chromogenic substrate for ... by -galactosidase generates a black insoluble ...
... form: Lyophilized powder containing ... Unit Definition: One unit ... 2-phosphoglycerate to phospho(enol)pyruvate per ... 25 C. Chem comp: ...
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... mm, No. of sidearm 4 ...
Biology Products: